Trial Profile
Multicenter, Randomized Phase Ⅲa Study of Genetically Modified Recombinant Human Interleukin-11 to Prevent Chemotherapy-induced Thrombocytopenia in Cancer Patients Receiving Chemotherapy
Status:
Completed
Phase of Trial:
Phase III
Latest Information Update: 17 Sep 2020
Price :
$35
*
At a glance
- Drugs NL 201 (Primary) ; Oprelvekin
- Indications Thrombocytopenia
- Focus Therapeutic Use
- Sponsors Beijing Northland Biotech
- 14 Sep 2020 Status changed from active, no longer recruiting to completed.
- 23 Mar 2015 Planned number of patients changed from 380 to 300 as reported by ClinicalTrials.gov record.
- 23 Mar 2015 Planned End Date changed from 1 Dec 2014 to 1 Aug 2017 as reported by ClinicalTrials.gov record.